Evidence map›Paper›PMID 32978690›Full record

ArticleThe AAPS journal2020

Bioavailability Enhancement and Food Effect Elimination of Abiraterone Acetate by Encapsulation in Surfactant-Enriched Oil Marbles.

Tereza Boleslavská, Ondřej Rychecký, Martin Krov, Pavel Žvátora, Ondřej Dammer, Josef Beránek, Petr Kozlík, Tomáš Křížek, Jana Hořínková, Pavel Ryšánek and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in The AAPS journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Tereza BoleslavskáZentiva, k.s., U Kabelovny 130, 102 37, Prague, Czech Republic.
Ondřej RycheckýZentiva, k.s., U Kabelovny 130, 102 37, Prague, Czech Republic.
Martin KrovDepartment of Chemical Engineering, University of Chemistry and Technology, Prague, Technická 5, 166 28, Prague, Czech Republic.
Pavel ŽvátoraZentiva, k.s., U Kabelovny 130, 102 37, Prague, Czech Republic.
Ondřej DammerZentiva, k.s., U Kabelovny 130, 102 37, Prague, Czech Republic.
Josef BeránekZentiva, k.s., U Kabelovny 130, 102 37, Prague, Czech Republic.
Petr KozlíkDepartment of Analytical Chemistry, Faculty of Science, Charles University, Prague, Czech Republic.
Tomáš KřížekDepartment of Analytical Chemistry, Faculty of Science, Charles University, Prague, Czech Republic.
Jana HořínkováInstitute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
Pavel RyšánekInstitute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
Jaroslava RoušarováInstitute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
Nikolina Kutinová CanováInstitute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
Martin ŠímaInstitute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
Ondřej SlanařInstitute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
František ŠtěpánekDepartment of Chemical Engineering, University of Chemistry and Technology, Prague, Technická 5, 166 28, Prague, Czech Republic. Frantisek.Stepanek@vscht.cz.ORCID 0000-0001-9288-4568
Charles University · CZUniversity of Chemistry and Technology, Prague · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Abiraterone acetate has limited bioavailability in the fasted state and exhibits a strong positive food effect. We present a novel formulation concept based on the so-called oil marbles (OMs) and show by in vitro and in vivo experiments that the food effect can be suppressed. OMs are spherical particles with a core-shell structure, formed by coating oil-based droplets that contain the dissolved drug by a layer of powder that prevents the cores from sticking and coalescence. OMs prepared in this work contained abiraterone acetate in the amorphous form and showed enhanced dissolution properties during in vitro experiments when compared with originally marketed formulation of abiraterone acetate (Zytiga

Indexed as

Abiraterone AcetateAdministration, OralAnimalsArea Under CurveBiological AvailabilityDrug CompoundingDrug LiberationFastingFood-Drug InteractionsMaleModels, AnimalOilsPharmaceutical VehiclesPostprandial PeriodRatsSurface-Active AgentsAbiraterone AcetateOilsPharmaceutical VehiclesSurface-Active Agentsbioavailabilitybioequivalencefood effectformulationliquid marble

Identifiers

PMID32978690
OpenAlexW3088497219

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.